Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® HCV / Hepatitis specialty page provides HCV / hepatitis-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


Sofosbuvir Found to Be Safe, Effective in Patients with Chronic Kidney Disease
A new study reveals that direct-acting antivirals, like sofosbuvir, may help improve kidney function in some patients.
Elbasvir & Grazoprevir Highly Efficacious in HCV Patients with Inherited Blood Disorders
Phase 3 study shows that combination of elbasvir and grazoprevir is highly efficacious in hepatitis C virus (HCV) infected patients with inherited blood disorders.
A Cost-Effective Method to Decrease HCV Infections in High-Risk Communities
Routine, rapid hepatitis C virus (HCV) testing may be a cost-effective method to help decrease the prevalence of new infections in high-risk communities.
Treatment for Hard-to-Reach Hepatitis C Patients May Improve with Integrated Care
The results of a new study have shown that an integrated care (IC) program can be successful in providing treatment to patients infected with hepatitis C virus (HCV) who were unlikely to respond to traditional outreach efforts.
Top 5 <i>Contagion</i>® News Articles for the Week of September 10, 2017
Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.
Study Finds No Significant Correlation Between Psoriasis and Prevalence of HBV and HCV
Researchers from the Department of Dermatology at the Northwestern University Feinberg School of Medicine have found no correlation between having psoriasis and the prevalence of hepatitis B or C.

NY Doctor's License Suspended Due to Inappropriate Infection Control Practices
The New York State Department of Health warns of potential disease exposure in two facility locations in Westchester County.
Janssen Halts HCV Drug Development & Turns Efforts Towards Fighting HBV
Janssen announces a strategic decision to discontinue the development of investigational hepatitis C treatment, JNJ-4178, a triple-combination drug, consisting of three direct-acting antivirals.
Big advances in treatment can